XRCC3 5′-UTR and IVS5-14 polymorphisms and breast cancer susceptibility: A meta-analysis

Breast Cancer Research and Treatment

Volumn 122, Issue 2, 2010, Pages 489-493

  Qiu, Li Xin ^a   Mao, Chen ^b   Yao, Lei ^c   Yu, Ke Da ^a   Zhan, Ping ^d   Chen, Bo ^e   Liu, Hai Guang ^f   Yuan, Hui ^g   Zhang, Jian ^a   Xue, Kai ^a   Hu, Xi Chun ^a  

^a FUDAN UNIVERSITY   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

^c FUDAN UNIVERSITY   (China)

^d NANJING CHEST HOSPITAL   (China)

^e NANJING MEDICAL UNIVERSITY   (China)

^f WENZHOU MEDICAL UNIVERSITY   (China)

^g ANHUI MEDICAL UNIVERSITY   (China)

Author keywords

Breast cancer; Meta analysis.; Polymorphism; Susceptibility; XRCC3

Indexed keywords

ADENOSINE; GUANOSINE; XRCC3 PROTEIN; DNA BINDING PROTEIN; X-RAY REPAIR CROSS COMPLEMENTING PROTEIN 3;

5' UNTRANSLATED REGION; ALLELE; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER RISK; CANCER SUSCEPTIBILITY; CASE CONTROL STUDY; CODOMINANCE; DNA POLYMORPHISM; DOMINANT INHERITANCE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; GENOTYPE; HUMAN; PRIORITY JOURNAL; RECESSIVE INHERITANCE; RISK ASSESSMENT; BREAST TUMOR; FEMALE; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS; METABOLISM; PHENOTYPE; REVIEW; RISK; RISK FACTOR;

5' UNTRANSLATED REGIONS; BREAST NEOPLASMS; DNA-BINDING PROTEINS; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; RISK ASSESSMENT; RISK FACTORS;

EID: 77955656364     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-009-0726-1     Document Type: Article

References (14)

1. Parkin DM, Bray F, Ferlay J, Pisani P (2005) Global cancer statistics 2002. CA Cancer J Clin 55:74-108.
2. Lichtenstein P, Holm NV, Verkasalo PK (2000) Environmental and heritable factors in the causation of cancer. N Engl J Med 343:78-85.
3. Brenneman MA, Weiss AE, Nickoloff JA, Chen DJ (2000) XRCC3 is required for efficient repair of chromosome breaks by homologous recombination. Mutat Res 459:89-97.
4. Breast Cancer Association Consortium (2006) Commonly studied single-nucleotide polymorphisms and breast cancer: results from the Breast Cancer Association Consortium. J Natl Cancer Inst 98:1382-1396.
5. Lee SA, Lee KM, Park SK, Choi JY, Kim B, Nam J, Yoo KY, Noh DY, Ahn SH, Kang D (2007) Genetic polymorphism of XRCC3 Thr241Met and breast cancer risk: case-control study in Korean women and meta-analysis of 12 studies. Breast Cancer Res Treat 103:71-76.
6. Manuguerra M, Saletta F, Karagas MR, Berwick M, Veglia F, Vineis P, Matullo G (2006) XRCC3 and XPD/ERCC2 single nucleotide polymorphisms and the risk of cancer: a HuGE review. Am J Epidemiol 164:297-302.
7. Economopoulos KP, Sergentanis TN (2009) XRCC3 Thr241Met polymorphism and breast cancer risk: a meta-analysis. Breast Cancer Res Treat. doi:10.1007/s10549-009-0562-3.
8. Han J, Hankinson SE, Ranu H, De Vivo I, Hunter DJ (2004) Polymorphisms in DNA double-strand break repair genes and breast cancer risk in the Nurses' Health Study. Carcinogenesis 25:189-195.
9. Kuschel B, Auranen A, McBride S, Novik KL, Antoniou A, Lipscombe JM, Day NE, Easton DF, Ponder BA, Pharoah PD (2002) Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum Mol Genet 11:1399-1407.
10. Garcia-Closas M, Egan KM, Newcomb PA, Brinton LA, Titus- Ernstoff L, Chanock S, Welch R, Lissowska J, Peplonska B, Szeszenia-Dabrowska N (2006) Polymorphisms in DNA doublestrand break repair genes and risk of breast cancer: two population- based studies in USA and Poland, and meta-analyses. Hum Genet 119:376-388.
11. Cochran WG (1954) The combination of estimates from different experiments. Biometrics 10:101-129.
12. Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22:719-748.
13. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7:177-188.
14. Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in metaanalysis detected by a simple, graphical test. BMJ 315: 629-634.